Intellia Therapeutics (NASDAQ:NTLA) Trading 9% Higher - Still a Buy?

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) traded up 9% during mid-day trading on Wednesday . The stock traded as high as $10.89 and last traded at $10.84. 2,200,953 shares changed hands during mid-day trading, a decline of 31% from the average session volume of 3,189,528 shares. The stock had previously closed at $9.94.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Oppenheimer reduced their price target on shares of Intellia Therapeutics from $60.00 to $40.00 and set an "outperform" rating for the company in a research report on Monday, January 13th. Chardan Capital raised their price objective on Intellia Therapeutics from $88.00 to $91.00 and gave the company a "buy" rating in a research note on Monday, November 18th. Citigroup dropped their price objective on Intellia Therapeutics from $25.00 to $19.00 and set a "neutral" rating on the stock in a research note on Friday, October 25th. Canaccord Genuity Group restated a "buy" rating and set a $90.00 price objective on shares of Intellia Therapeutics in a research note on Tuesday, November 19th. Finally, Barclays dropped their price objective on Intellia Therapeutics from $76.00 to $55.00 and set an "overweight" rating on the stock in a research note on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $51.06.

Intellia Therapeutics Trading Up 10.8 %

The firm has a market cap of $1.12 billion, a PE ratio of -2.02 and a beta of 1.83. The stock has a fifty day simple moving average of $12.86 and a two-hundred day simple moving average of $18.29.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) EPS for the quarter, topping the consensus estimate of ($1.37) by $0.03. The business had revenue of $9.10 million for the quarter, compared to analysts' expectations of $8.28 million. During the same period in the previous year, the firm posted ($1.38) EPS. The firm's revenue for the quarter was down 24.1% compared to the same quarter last year. As a group, sell-side analysts predict that Intellia Therapeutics, Inc. will post -5.09 earnings per share for the current fiscal year.

Insider Transactions at Intellia Therapeutics

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the company's stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $326,509.26. Following the completion of the sale, the chief executive officer now owns 941,115 shares of the company's stock, valued at $11,462,780.70. This represents a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders sold 28,735 shares of company stock valued at $349,909. 3.20% of the stock is owned by corporate insiders.

Institutional Trading of Intellia Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. KBC Group NV lifted its position in Intellia Therapeutics by 62.4% in the fourth quarter. KBC Group NV now owns 6,093 shares of the company's stock valued at $71,000 after purchasing an additional 2,340 shares during the last quarter. SG Americas Securities LLC raised its holdings in shares of Intellia Therapeutics by 85.7% during the fourth quarter. SG Americas Securities LLC now owns 44,838 shares of the company's stock valued at $523,000 after acquiring an additional 20,694 shares in the last quarter. Avanza Fonder AB bought a new position in shares of Intellia Therapeutics during the fourth quarter valued at approximately $421,000. Hennion & Walsh Asset Management Inc. raised its holdings in shares of Intellia Therapeutics by 125.2% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 120,997 shares of the company's stock valued at $1,411,000 after acquiring an additional 67,276 shares in the last quarter. Finally, Signal Advisors Wealth LLC raised its holdings in shares of Intellia Therapeutics by 59.9% during the fourth quarter. Signal Advisors Wealth LLC now owns 74,158 shares of the company's stock valued at $865,000 after acquiring an additional 27,782 shares in the last quarter. Institutional investors own 88.77% of the company's stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.